Back to Search Start Over

pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma

Authors :
Chiara Castelli
Simone Carradori
Licia Rivoltini
Davide Citterio
Barbara Vergani
Antonello Villa
Massimo Milione
Vincenzo Mazzaferro
Olga Kuchuk
Malcolm R. Alison
Alessandra Tuccitto
Claudiu T. Supuran
Chiara Camisaschi
Veronica Huber
Kuchuk, O
Tuccitto, A
Citterio, D
Huber, V
Camisaschi, C
Milione, M
Vergani, B
Villa, A
Alison, M
Carradori, S
Supuran, C
Rivoltini, L
Castelli, C
Mazzaferro, V
Source :
OncoImmunology, Vol 7, Iss 7 (2018), Oncoimmunology
Publication Year :
2018
Publisher :
Taylor and Francis Inc., 2018.

Abstract

Interfering with tumor metabolism is an emerging strategy for treating cancers that are resistant to standard therapies. Featuring a rapid proliferation rate and exacerbated glycolysis, hepatocellular carcinoma (HCC) creates a highly hypoxic microenvironment with excessive production of lactic and carbonic acids. These metabolic conditions promote disease aggressiveness and cancer-related immunosuppression. The pH regulatory molecules work as a bridge between tumor cells and their surrounding milieu. Herein, we show that the pH regulatory molecules CAIX, CAXII and V-ATPase are overexpressed in the HCC microenvironment and that interfering with their pathways exerts antitumor activity. Importantly, the V-ATPase complex was expressed by M2-like tumor-associated macrophages. Blocking ex vivo V-ATPase activity established a less immune-suppressive tumor microenvironment and reversed the mesenchymal features of HCC. Thus, targeting the unique cross-talk between tumor cells and the tumor microenvironment played by pH regulatory molecules holds promise as a strategy to control HCC progression and to reduce the immunosuppressive pressure mediated by the hypoxic/acidic metabolism, particularly considering the potential combination of this strategy with emerging immune checkpoint-based immunotherapies.

Details

Language :
English
Database :
OpenAIRE
Journal :
OncoImmunology, Vol 7, Iss 7 (2018), Oncoimmunology
Accession number :
edsair.doi.dedup.....2a557a5c68d609f446ad7f5939cd9b1d